ArticleBMC biotechnology2019
Ex vivo evolution of human antibodies by CRISPR-X: from a naive B cell repertoire to affinity matured antibodies.
Article in BMC biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Editor's Choice Protein engineering strategies to develop lectins by design.Glycobiology · 2025Review
- A Rapid Antibody Enhancement Platform inACS synthetic biology · 2023Article
- Base editor screens for in situ mutational scanning at scale.Molecular cell · 2023Review
- A cluster of broadly neutralizing IgG against BK polyomavirus in a repertoire dominated by IgM.Life science alliance · 2023Article
- Methods and cell-based strategies to produce antibody libraries: current state.Applied microbiology and biotechnology · 2021Review
- Genome editor-directed in vivo library diversification.Cell chemical biology · 2021Review
- Approaches to Enhance Precise CRISPR/Cas9-Mediated Genome Editing.International journal of molecular sciences · 2021Review
- Directed evolution in mammalian cells.Nature methods · 2021Review
- Full-Spectrum Targeted Mutagenesis in Plant and Animal Cells.International journal of molecular sciences · 2021Review
- Broadly Neutralizing Bovine Antibodies: Highly Effective New Tools against Evasive Pathogens?Viruses · 2020Review
- The rapidly advancing Class 2 CRISPR-Cas technologies: A customizable toolbox for molecular manipulations.Journal of cellular and molecular medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.